Riskpilot← Back to searchSign inGet full accessRotsevni AB
ABActiveOrg 5593062275Köpsvängen 10Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20211-4 employees
Revenue 2024
SEK 932K
+3688% vs 2023
EBITDA margin
2.3%
+212% vs 2023
Equity ratio
-21.6%
Financial strength
Net profit 2024
SEK -2K
+98% vs 2023
| Revenue | SEK 932K | +3688% |
| EBITDA | SEK 21K | +212% |
| Net profit | SEK -2K | +98% |
| Total assets | SEK 545K | +81% |
| Equity | SEK -118K | -2% |
| Employees | — | — |
Legal name
Rotsevni AB
Org number
5593062275
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
9 mars 2021
Share capital
SEK 25 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska förvärva och förvalta aktier och annan lös egendom. Bolaget ska även bedriva konsultverksamhet avseende företags organisation. Därutöver ska bolaget bedriva personaluthyrning, försäljning av apoteksvaror inom egenvård, förmedling av läkemedel och jobba med partihandel samt därmed förenlig verksamhet.
Address
Köpsvängen 10
Email
leith.yassir@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 261 | 342 | 25 | 932 |
| Staff expenses | — | — | −0 | −86 |
| EBITDA | 244 | 305 | 7 | 21 |
| Depreciation & amort. | −0 | — | — | — |
| EBIT | 244 | 305 | 7 | 21 |
| Net financials | — | −3 | −1 | −23 |
| Profit before tax | 0 | −4 | −137 | −2 |
| Tax | −0 | — | — | — |
| Net profit | 0 | −4 | −137 | −2 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 105 | 120 | 301 | 545 |
| Equity | 25 | 21 | −115 | −118 |
| Long-term debt | 0 | — | 250 | 140 |
| Short-term debt | 80 | 99 | 166 | 523 |
| Total debt | 80 | 99 | 416 | 663 |
EBITDA margin
2.3%
This company
15.8%
Market median
-85% vs market
20212024
Equity ratio
-21.6%
This company
38.2%
Market median
-157% vs market
20212024
Return on equity
-225500.0%
This company
18.4%
Market median
-1225643% vs market
20212024
Net profit margin
-0.2%
This company
8.1%
Market median
-102% vs market
20212024
Asset turnover
1.71×
This company
1.12×
Market median
+53% vs market
20212024
Debt / equity
5.64×
This company
0.62×
Market median
-810% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-03-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LA Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (1) | ||
LY Chief Executive Officer | Chief Executive Officer | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Rotsevni AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lilas Yassir | Chief Executive Officer | 0 companies |
| Leith Abdul Wahid Yassir | Chief Executive Officer | 0 companies |
| Hamon Hosseini | Deputy Board Member | 0 companies |